Scientists present wireless glucose monitoring methodology, best practices, research findings, and discuss the power of continuous glucose profiles, particularly when combined with other gold standard assays to study obesity, diabetes and cardiovascular related diseases.

The most commonly used method for measuring glucose in preclinical research remains intermittent blood sampling. However, continuous glucose monitoring via implantable telemetry offers numerous benefits over periodic measurements, including larger sample counts, improved animal welfare and higher data quality, to name a few. When appropriate for the study, monitoring physiological events with telemetry allows for continuous data collection from fewer animals who are conscious, freely moving, and under minimal stress from handling. The simultaneous acquisition of a continuous glucose profile with physiologic telemetry measurements will arm researchers with unique scientific information sure to advance scientific discovery, improve our understanding of disease and in turn help develop effective treatments.

During this webinar sponsored by Data Sciences International (DSI), Stephanie Simonds, PhD shares novel research conducted using implantable glucose telemetry for basic analysis and combination studies investigating the effects of drugs and hormones in mice. Specifically, she discusses research case studies involving Designer Receptors Exclusively Activated by Designer Drugs (DREADDs) and adeno-associated virus neuronal knockdown models, and speaks to the importance of collecting continuous glucose data simultaneously with physiologic telemetry measurements.

In addition, Dr. Megan Fine from DSI’s Surgical Services team presents the surgical techniques and best practices that her team has developed for use with glucose telemetry. She discusses the use of this technology in a variety of animal models, including recommendations for surgery and techniques to help ensure successful calibrations. Finally, Megan highlights the concurrent collection of multiple endpoints, such as glucose and cardiovascular data, in the same subject.

Click to watch the webinar recording. To view the presentation full screen simply click the square icon located in the bottom-right corner of the video-viewer.

Resources

To retrieve a PDF copy of the presentation, click on the link below the slide player. From this page, click on the “Download” link to retrieve the file.

Presenters

Fellow
National Heart Foundation of Australia Postdoctoral

Veterinary Surgeon
Data Sciences International

Production Partner

Data Sciences International

Data Sciences International (DSI) is the leader in preclinical physiological monitoring offering telemetry, instrumentation, software and services to help advance science. Industries served include: Pharmaceuticals, Academia, Contract Research Organizations, Biological and Chemical Defense, Medical Devices, Government, and Biotechnology.

Harvard Bioscience, Inc.

Harvard Bioscience is a global leader in the manufacturing and distribution of solutions to advance life science research. For over 110 years, we have served the changing needs of life scientists in over 100 countries. Our expanding portfolio of brands include instruments for organ and animal research, cell analysis, molecular biology, fluidics, and laboratory consumables.

Additional Content From Data Sciences International

Additional Content From Harvard Bioscience, Inc.

Related Content